MX2019010812A - Proteinas de fusion inmunomoduladoras y sus usos. - Google Patents

Proteinas de fusion inmunomoduladoras y sus usos.

Info

Publication number
MX2019010812A
MX2019010812A MX2019010812A MX2019010812A MX2019010812A MX 2019010812 A MX2019010812 A MX 2019010812A MX 2019010812 A MX2019010812 A MX 2019010812A MX 2019010812 A MX2019010812 A MX 2019010812A MX 2019010812 A MX2019010812 A MX 2019010812A
Authority
MX
Mexico
Prior art keywords
fusion proteins
immunomodulating
immunomodulatory fusion
relates
cell
Prior art date
Application number
MX2019010812A
Other languages
English (en)
Spanish (es)
Inventor
M Schmitt Thomas
D Greenberg Philip
K Oda Shannon
Original Assignee
Hutchinson Fred Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchinson Fred Cancer Res filed Critical Hutchinson Fred Cancer Res
Publication of MX2019010812A publication Critical patent/MX2019010812A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2019010812A 2017-03-17 2018-03-16 Proteinas de fusion inmunomoduladoras y sus usos. MX2019010812A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762473282P 2017-03-17 2017-03-17
US201862629663P 2018-02-12 2018-02-12
PCT/US2018/022998 WO2018170475A1 (en) 2017-03-17 2018-03-16 Immunomodulatory fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
MX2019010812A true MX2019010812A (es) 2019-12-11

Family

ID=61911694

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019010812A MX2019010812A (es) 2017-03-17 2018-03-16 Proteinas de fusion inmunomoduladoras y sus usos.
MX2024000006A MX2024000006A (es) 2017-03-17 2019-09-11 Proteinas de fusion inmunomoduladoras y sus usos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024000006A MX2024000006A (es) 2017-03-17 2019-09-11 Proteinas de fusion inmunomoduladoras y sus usos.

Country Status (8)

Country Link
US (2) US11725210B2 (enExample)
EP (1) EP3595706A1 (enExample)
JP (3) JP2020511136A (enExample)
CN (2) CN110621335B (enExample)
AU (1) AU2018236461B2 (enExample)
CA (1) CA3055784A1 (enExample)
MX (2) MX2019010812A (enExample)
WO (1) WO2018170475A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1246317A1 (zh) * 2015-03-05 2018-09-07 Fred Hutchinson Cancer Center 免疫调节融合蛋白及其用途
MX2019007611A (es) 2016-12-22 2020-07-29 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso.
AU2018234628B2 (en) 2017-03-15 2023-07-20 Cue Biopharma, Inc. Methods for modulating an immune response
JP2020511136A (ja) 2017-03-17 2020-04-16 フレッド ハッチンソン キャンサー リサーチ センター 免疫調節性融合タンパク質およびその使用
TW201920249A (zh) 2017-09-07 2019-06-01 美商信號生物製藥公司 具有結合位點之t細胞調節多聚體多肽及其使用方法
AU2019335014A1 (en) * 2018-09-05 2021-03-25 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
EP3856769A4 (en) * 2018-09-28 2022-08-17 Memorial Sloan Kettering Cancer Center IMMUNOREACTIVE CELLS EXPRESSING DOMINANT NEGATIVE FAS AND USES THEREOF
GB2569692A (en) * 2018-10-30 2019-06-26 Tc Biopharm Ltd T cell antigen receptor chimera
EP3897690A4 (en) * 2018-12-19 2022-09-28 Cue Biopharma, Inc. T LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
TWI856047B (zh) * 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
US12419913B2 (en) 2019-02-08 2025-09-23 Dna Twopointo, Inc. Modification of CAR-T cells
WO2020163755A1 (en) * 2019-02-08 2020-08-13 Dna Twopointo Inc. Transposon-based modifications of immune cells
CA3148072A1 (en) * 2019-07-19 2021-01-28 Memorial Sloan-Kettering Cancer Center Fusion polypeptide for immunotherapy
AU2020342544A1 (en) * 2019-09-05 2022-03-24 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
WO2021051195A1 (en) * 2019-09-16 2021-03-25 Mcmaster University Chimeric costimulatory receptors and methods and uses thereof
CN110790842B (zh) * 2019-11-25 2021-03-30 贵州康钦承平生物科技有限公司 一种FasL-CAR融合蛋白和表达融合蛋白的T细胞及其制备方法和应用
WO2021141985A1 (en) * 2020-01-06 2021-07-15 Memorial Sloan-Kettering Cancer Center Novel dominant negative fas polypeptides, cells comprising thereof and uses thereof
US20230121433A1 (en) * 2020-03-11 2023-04-20 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
GB202101491D0 (en) 2021-02-03 2021-03-17 Autolus Ltd Molecule
CN115315439A (zh) * 2020-04-09 2022-11-08 奥托路斯有限公司 细胞
EP4132962A1 (en) 2020-04-09 2023-02-15 Autolus Limited Molecule
MX2022013208A (es) 2020-05-12 2022-11-14 Cue Biopharma Inc Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos.
CN113698490B (zh) * 2020-05-22 2024-04-30 重庆精准生物技术有限公司 靶向cea的缺氧诱导启动的car结构及免疫细胞和应用
EP4182338A1 (en) 2020-07-17 2023-05-24 Instil Bio (Uk) Limited Receptors providing targeted costimulation for adoptive cell therapy
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
EP4355340A4 (en) 2021-06-16 2025-05-21 Instil Bio, Inc. RECEPTORS FOR TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY
EP4370213A4 (en) 2021-07-16 2025-06-04 Instil Bio (Uk) Limited Chimeric molecules for targeted costimulation for adoptive cell therapy
CN113621077B (zh) * 2021-09-02 2023-01-31 山东大学 一种tim-3/cd28融合蛋白及所述融合蛋白修饰的car-t细胞
US20250136662A1 (en) * 2021-11-25 2025-05-01 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Cd95 polypeptides
WO2023150801A2 (en) * 2022-02-07 2023-08-10 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Recombinant proteins that stimulate an immune response in the presence of naturally inhibitory ligand binding
CA3244596A1 (en) * 2022-03-29 2023-10-05 Allogene Therapeutics Inc Chimeric switch receivers for converting immunoactive signals into stimulation signals
KR20250037713A (ko) * 2022-05-23 2025-03-18 아피니-티 테라퓨틱스, 인크. 신항원에 특이적인 결합 단백질과 조작 세포 및 이의 용도
EP4293040A1 (en) 2022-06-19 2023-12-20 ETH Zurich Cell line for engineering cytokine receptors
WO2024046468A1 (en) * 2022-09-02 2024-03-07 Nanjing Legend Biotech Co., Ltd. Fusion proteins targeting lysosomal degradation pathway
KR20240095012A (ko) * 2022-11-29 2024-06-25 (주) 테라베스트 Cd137 세포외 도메인을 포함하는 융합단백질, 이를 발현하는 면역세포 및 이의 용도
WO2024193714A1 (zh) * 2023-03-23 2024-09-26 科济生物医药（上海）有限公司 细胞免疫疗法的组合物和方法
WO2025006795A1 (en) * 2023-06-30 2025-01-02 Board Of Regents, The University Of Texas System Tsyn-seq: a t cell synapse-based tumor antigen identification platform
WO2025081123A1 (en) 2023-10-12 2025-04-17 Fred Hutchinson Cancer Center Methods and compositions for improving t cell immunotherapy
WO2025117773A2 (en) * 2023-11-30 2025-06-05 Affini-T Therapeutics, Inc. Compositions and methods for treating neoplasia
EP4599843A1 (en) 2024-02-09 2025-08-13 Fundació Institut de recerca de l'Hospital de la Santa Creu i Sant Pau Car and modified cd200r combination
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1999A (en) 1841-03-12 Improvement in seed-planters
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
JP4137997B2 (ja) 1994-01-11 2008-08-20 ダイアックス コープ． クニッツドメインから誘導されたヒトプラスミンの阻害剤
CA2204183A1 (en) 1994-11-01 1996-05-09 Andrew Lawrence Feldhaus Chimeric receptors for the generation of selectively-activatable th-independent cytotoxic t cells
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
WO2006000830A2 (en) 2004-06-29 2006-01-05 Avidex Ltd Cells expressing a modified t cell receptor
ATE414718T1 (de) 2005-01-05 2008-12-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
GB0504767D0 (en) 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
EP1829895A1 (en) 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
US9365629B2 (en) 2007-09-24 2016-06-14 University Of Zurich Designed armadillo repeat proteins
US9163258B2 (en) 2010-07-23 2015-10-20 Fred Hutchinson Cancer Research Center Method for the treatment of obesity
WO2012042480A1 (en) 2010-09-28 2012-04-05 Kahr Medical Ltd. Compositions and methods for treatment of hematological malignancies
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
MX359513B (es) 2011-03-23 2018-10-01 Hutchinson Fred Cancer Res Metodo y composiciones para inmunoterapia celular.
CA2832569A1 (en) 2011-04-08 2012-10-11 Baylor College Of Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
EP3915588A1 (en) 2011-07-29 2021-12-01 The Trustees of the University of Pennsylvania Switch costimulatory receptors
US9688740B2 (en) 2011-10-26 2017-06-27 National Cancer Center Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy
US9447194B2 (en) 2012-02-13 2016-09-20 Seattle Children's Hospital Bispecific chimeric antigen receptors and encoding polynucleotides thereof
WO2013192294A1 (en) * 2012-06-20 2013-12-27 Boston 3T Biotechnologies, Inc. Cellular therapies for treating and preventing cancers and other immune system disorders
EP2941438A1 (en) 2013-01-01 2015-11-11 Kahr Medical Ltd. Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
US20160008399A1 (en) 2013-01-14 2016-01-14 Fred Hutchinson Cancer Research Center Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
CN103965361B (zh) 2013-02-06 2018-10-30 上海细胞治疗工程技术研究中心集团有限公司 一种t细胞信号的嵌合分子转换器及其用途
CN105452287A (zh) 2013-04-17 2016-03-30 贝勒医学院 免疫抑制性TGF-β信号转换器
US10568947B2 (en) 2014-07-21 2020-02-25 Novartis Ag Treatment of cancer using a CLL-1 chimeric antigen receptor
MX390943B (es) 2014-07-21 2025-03-21 Novartis Ag Receptores de antígeno quimérico cd33 y usos de los mismos.
MY181834A (en) 2014-07-21 2021-01-08 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
ES2841274T3 (es) 2014-08-04 2021-07-07 Hutchinson Fred Cancer Res Inmunoterapia con células T específica para WT-1
MX377196B (es) 2014-08-15 2025-03-07 Merck Patent Gmbh Proteinas de fusion de inmunoglobulina de la proteina alfa reguladora de señal (sirp-alfa).
KR102376242B1 (ko) 2014-12-24 2022-03-21 오토러스 리미티드 세포
EP3247808B1 (en) 2015-01-21 2021-05-05 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
HK1246317A1 (zh) * 2015-03-05 2018-09-07 Fred Hutchinson Cancer Center 免疫调节融合蛋白及其用途
CA2989949A1 (en) 2015-06-19 2016-12-22 Sebastian KOBOLD Pd-1-cd28 fusion proteins and their use in medicine
JP6976960B2 (ja) 2015-11-27 2021-12-08 カーサリクス プロプライエタリー リミテッド 遺伝子改変された細胞およびその使用
US11026969B2 (en) 2015-12-23 2021-06-08 Fred Hutchinson Cancer Research Center High affinity T cell receptors and uses thereof
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
CN109312304A (zh) 2016-04-20 2019-02-05 弗雷德哈钦森癌症研究中心 免疫调节性il2r融合蛋白及其用途
JP2020511136A (ja) 2017-03-17 2020-04-16 フレッド ハッチンソン キャンサー リサーチ センター 免疫調節性融合タンパク質およびその使用
WO2019061012A1 (zh) 2017-09-26 2019-04-04 南京凯地生物科技有限公司 靶向cd47的特异性嵌合抗原受体t细胞的制备及其应用
CN110330567B (zh) 2019-07-02 2020-11-06 南京凯地生物科技有限公司 双特异性嵌合抗原受体t细胞，其制备方法和应用

Also Published As

Publication number Publication date
US20240218379A1 (en) 2024-07-04
CN110621335B (zh) 2025-06-03
CN110621335A (zh) 2019-12-27
CN119409836A (zh) 2025-02-11
JP2020511136A (ja) 2020-04-16
WO2018170475A1 (en) 2018-09-20
MX2024000006A (es) 2024-02-20
JP2024019732A (ja) 2024-02-09
US20200009190A1 (en) 2020-01-09
JP7465306B2 (ja) 2024-04-10
US11725210B2 (en) 2023-08-15
US12365906B2 (en) 2025-07-22
AU2018236461A1 (en) 2019-09-19
AU2018236461B2 (en) 2025-03-27
JP2022113880A (ja) 2022-08-04
EP3595706A1 (en) 2020-01-22
CA3055784A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
MX2024000006A (es) Proteinas de fusion inmunomoduladoras y sus usos.
MX2022006002A (es) Proteinas de fusion inmunomoduladoras y usos de las mismas.
MX2019001458A (es) Polipeptidos modificados y usos de los mismos.
MX2017008875A (es) Anticuerpos biespecificos contra cd3 y cd20.
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
WO2014116846A3 (en) Methods and compositions for modulating an immune response
BR112018012707A2 (pt) inibidores da interação de menin-mll
MX2018015252A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
GB2570593A (en) Methods relating to intestinal organ-on-a-chip
AU367014S (en) Aircraft
MX2015013590A (es) Sistemas y metodos para la produccion dirigids de una proteina terapeutica dentro de una celula objetivo.
MX2018004121A (es) Receptores de antigeno y usos de los mismos.
MX2019008359A (es) Cadena j modificada.
AU201614890S (en) Medical shield remover
AU201614892S (en) Medical shield remover
PE20151774A1 (es) Construcciones de proteinas mitocondriales y sus usos
AU201713597S (en) Auto-injector
MX390494B (es) UNA NUEVA SUBPOBLACIÓN DE TREGS CD8+CD45RCbajo Y SUS USOS.
MX2016013631A (es) Celulas huespedes modificadas y usos de las mismas.
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
BR112018070139A2 (pt) expressão de proteínas em bactérias gram-negativas em que a razão entre o volume periplasmático e o volume citoplasmático é entre 0,5:1 e 10:1
MX2022003047A (es) Receptores de reconocimiento de antígenos dirigidos a cd371 y usos de los mismos.
MX372803B (es) Polipeptidos de fusion relacionados con omega-hidroxilasa con propiedades mejoradas.
CR20160225A (es) Glicoproteínas recombinantes y sus usos